- Home
- OP vs SBFM Comparison
OP vs SBFM Comparison
Compare OP & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- SBFM
- Stock Information
- Founded
- OP 2021
- SBFM 2006
- Country
- OP Greece
- SBFM United States
- Employees
- OP N/A
- SBFM N/A
- Industry
- OP
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- SBFM Health Care
- Exchange
- OP Nasdaq
- SBFM Nasdaq
- Market Cap
- OP 5.3M
- SBFM 4.6M
- IPO Year
- OP N/A
- SBFM N/A
- Fundamental
- Price
- OP $0.82
- SBFM $1.50
- Analyst Decision
- OP
- SBFM Strong Buy
- Analyst Count
- OP 0
- SBFM 1
- Target Price
- OP N/A
- SBFM $15.00
- AVG Volume (30 Days)
- OP 33.8K
- SBFM 784.6K
- Earning Date
- OP 06-05-2025
- SBFM 05-15-2025
- Dividend Yield
- OP N/A
- SBFM N/A
- EPS Growth
- OP N/A
- SBFM N/A
- EPS
- OP N/A
- SBFM N/A
- Revenue
- OP $25,702,000.00
- SBFM $34,874,283.00
- Revenue This Year
- OP N/A
- SBFM $192.48
- Revenue Next Year
- OP N/A
- SBFM N/A
- P/E Ratio
- OP N/A
- SBFM N/A
- Revenue Growth
- OP 35.58
- SBFM 44.75
- 52 Week Low
- OP $0.63
- SBFM $1.17
- 52 Week High
- OP $2.71
- SBFM $23.20
- Technical
- Relative Strength Index (RSI)
- OP 61.64
- SBFM 52.85
- Support Level
- OP $0.65
- SBFM $1.24
- Resistance Level
- OP $0.75
- SBFM $1.41
- Average True Range (ATR)
- OP 0.05
- SBFM 0.10
- MACD
- OP 0.02
- SBFM 0.04
- Stochastic Oscillator
- OP 99.94
- SBFM 87.88
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.